Fulvestrant Superior to Anastrozole in Extending Progression-Free Survival in Patients with Breast Cancer

TON - September 2016, Vol 9, No 5 - Breast Cancer
Sophie Granger

In patients with hormone receptor (HR)-positive, locally advanced or metastatic breast cancer, treatment with fulvestrant (Faslodex) demonstrated superiority over anastrozole (Arimidex) in achieving extended progression-free survival, according to a recent press release from AstraZeneca.

This information comes from the primary end point results of the randomized, double-blind, phase 3 FALCON (Fulvestrant and Anastrozole Compared in Hormonal Therapy Naïve Advanced Breast Cancer) trial, which is an ongoing study comparing the effects of fulvestrant 500 mg and anastrozole 1 mg on disease progression in women with HR-positive locally advanced or metastatic breast cancer who have not received previous hormonal treatment. The adverse event profile was largely consistent with the current safety profile of these drugs.

Currently, aromatase inhibitors (eg, anastrozole) are standard of care for this patient population.

“The FALCON results bring us closer to offering more and earlier treatment options to postmenopausal women with HR-positive locally advanced or metastatic breast cancer; the potential to delay disease progression is important for these patients as there is currently no cure,” stated Sean Bohen, MD, PhD, Chief Medical Officer, AstraZeneca, in the press release.

A full evaluation of FALCON trial data is still being conducted, with results expected to be presented later in 2016.

Source: AstraZeneca’s Faslodex Met Primary Endpoint in First-Line Treatment of Advanced Breast Cancer [news release]. London, United Kingdom: AstraZeneca; May 27, 2016. www.astrazeneca.com/media-centre/press-releases/ 2016/astrazenecas-faslodex-met-primary-endpoint-in-first-line-treatment-of-advanced-breast-cancer.html. Accessed June 1, 2016.

Related Items
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
Rebecca Bailey
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Breast Cancer, Immunotherapy
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TON Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only, In the News
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Breast Cancer, Drug Updates & News, ESMO
Blood-Based Biopsy Can Predict Breast Cancer Recurrence
TON Web Exclusives published on February 26, 2018 in Breast Cancer
The Benefit of CDK4/6 Inhibitors Applies Equally to Older Women with Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
Immunotherapy Continues to Gain Momentum in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Arm Morbidity Higher with Extensive Lymph Node Surgery in Younger Patients with Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Dose-Intense Chemotherapy Shown to Improve Outcomes in Patients with Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Last modified: September 14, 2016